# GlenmarkPharma

Generated by Yoast SEO v28.5, this is an llms.txt file, meant for consumption by LLMs.

## Pages
- [Sustainibility](https://glenmarkpharma.com/sustainibility/)
- [Global \- Europe](https://glenmarkpharma.com/global-presence/global-europe/)
- [Global \- Latin America](https://glenmarkpharma.com/global-presence/global-latin-america/)
- [Home](https://glenmarkpharma.com/)
- [Oncology](https://glenmarkpharma.com/oncology/)

## Press Release
- [Glenmark Pharmaceuticals receives Establishment Inspection Report \(EIR\) from U\.S\. FDA for its Goa facility with VAI classification](https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-receives-establishment-inspection-report-eir-from-u-s-fda-for-its-goa-facility-with-vai-classification/)
- [Glenmark Expands Global Respiratory Innovation Footprint with RYALTRIS® Launch in Brazil](https://glenmarkpharma.com/press_release/glenmark-expands-global-respiratory-innovation-footprint-with-ryaltris-launch-in-brazil/)
- [Glenmark Pharmaceuticals Inc\., USA launches Calcium Gluconate Injection USP, 1,000 mg/10 mL \(100 mg/mL\), 5,000 mg/50 mL \(100 mg/mL\) Single\-Dose Vials and 10,000 mg/100 mL \(100 mg/mL\) Pharmacy Bulk Package](https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-inc-usa-launches-calcium-gluconate-injection-usp-1000-mg-10-ml-100-mg-ml-5000-mg-50-ml-100-mg-ml-single-dose-vials-and-10000-mg-100-ml-100-mg-ml-pharmacy-bulk-pac/)
- [Glenmark Pharmaceuticals receives U\.S\. FDA approval for Fluticasone Propionate Nasal Spray, 0\.05 mg \(50 mcg\)/spray](https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-receives-u-s-fda-approval-for-fluticasone-propionate-nasal-spray-0-05-mg-50-mcg-spray/)
- [Glenmark Pharmaceuticals Announces Q1 FY27 Results](https://glenmarkpharma.com/press_release/glenmark-pharmaceuticals-announces-q1-fy27-results/)

## Quarterly Results
- [Earnings Call Transcript Q1 FY27](https://glenmarkpharma.com/quarterly_results/earnings-call-transcript-q1-fy27/)
- [Earnings Call Recording Q1 FY27](https://glenmarkpharma.com/quarterly_results/earnings-call-recording-q1-fy27/)
- [MDA Q1 FY 27](https://glenmarkpharma.com/quarterly_results/mda-q1-fy-27/)
- [Unaudited financial results Q1 FY27](https://glenmarkpharma.com/quarterly_results/unaudited-financial-results-q1-fy27/)
- [Earnings Call Intimation Q1 FY27](https://glenmarkpharma.com/quarterly_results/earnings-call-intimation-q1-fy27/)

## Annual Reports
- [AGM Proceedings \& Scrutinizer Report 2025\-26](https://glenmarkpharma.com/annual_reports/agm-proceedings-scrutinizer-report-2025-26/)
- [Annual Report 2025\-26](https://glenmarkpharma.com/annual_reports/annual-report-2025-26/)
- [Annual Return 2025\-26](https://glenmarkpharma.com/annual_reports/annual-return-2025-26/)
- [AGM Notice 2025\-26](https://glenmarkpharma.com/annual_reports/agm-notice-2025-26/)
- [Annual Secretarial Compliance Report 2025 \- 26](https://glenmarkpharma.com/annual_reports/annual-secretarial-compliance-report-2025-26/)

## Investor Presentations
- [Q2 FY26](https://glenmarkpharma.com/investorpresentation/q2-fy26/)
- [Q1 FY 27](https://glenmarkpharma.com/investorpresentation/q1-fy-27/)
- [Investor Day 2026](https://glenmarkpharma.com/investorpresentation/investor-day-2026/)
- [Q4 FY26](https://glenmarkpharma.com/investorpresentation/q4-fy26/)
- [Q2 FY25](https://glenmarkpharma.com/investorpresentation/q2-fy25/)

## Other Announcements
- [Intimation of Trading Window Closure \(Q2\)](https://glenmarkpharma.com/other_announcements/intimation-of-trading-window-closure-q2/)
- [Intimation of Schedule of Analyst / Institutional Investor Meeting](https://glenmarkpharma.com/other_announcements/intimation-of-schedule-of-analyst-institutional-investor-meeting/)
- [Scrutinizer Report 2025\-26](https://glenmarkpharma.com/other_announcements/scrutinizer-report-2025-26/)
- [Credit Rating – India Ratings  and Research](https://glenmarkpharma.com/other_announcements/credit-rating-india-ratings-and-research/)
- [Newspaper Advertisement – Special Window](https://glenmarkpharma.com/other_announcements/newspaper-advertisement-special-window-3/)

## Shareholding Patterns
- [Q1](https://glenmarkpharma.com/shareholding_pattern/q1-8/)
- [Q4](https://glenmarkpharma.com/shareholding_pattern/q4-8/)
- [Q3](https://glenmarkpharma.com/shareholding_pattern/q3-8/)
- [Q2](https://glenmarkpharma.com/shareholding_pattern/q2-8/)
- [Q1](https://glenmarkpharma.com/shareholding_pattern/q1-7/)

## Reconciliation of Share Capital Audit Report
- [Q1](https://glenmarkpharma.com/reconciliation_share/q1-9/)
- [Q4](https://glenmarkpharma.com/reconciliation_share/q4-8/)
- [Q2](https://glenmarkpharma.com/reconciliation_share/q2-2/)
- [Q3](https://glenmarkpharma.com/reconciliation_share/q3-8/)
- [Q2](https://glenmarkpharma.com/reconciliation_share/q2-8/)

## Integrated Corporate Governance Report
- [Q1](https://glenmarkpharma.com/integrated_corporate/q1-9/)
- [Q4](https://glenmarkpharma.com/integrated_corporate/q4-8/)
- [Q3](https://glenmarkpharma.com/integrated_corporate/q3-8/)
- [Q2](https://glenmarkpharma.com/integrated_corporate/q2-8/)
- [Q1](https://glenmarkpharma.com/integrated_corporate/q1-8/)

## Optional
- [Sitemap index](https://glenmarkpharma.com/sitemap_index.xml)